Chenodeoxycholic acid suppresses colorectal cancer by activating Farnesoid X receptor
American Journal of Cancer Research · 2026 · 16 (7) · 2801-2813
DOI: 10.62347/bzhd6251 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Jun Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital) Wuxi 214023, Jiangsu, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide. Therefore, it is critical to identify accurate biomarkers for improving early diagnosis and clinical outcomes. In our study, serum was collected from 90 healthy controls and 98 CRC patients after 8-hour fasting, followed by the measurement of chenodeoxycholic acid (CDCA) levels using ELISA. Cell proliferation and metastasis were assessed using MTT, colony-forming, and transwell assays. Farnesoid X receptor (FXR) was silenced with shFXR lentivirus, and its expression in tumors was analyzed by RT-qPCR. The result revealed that serum CDCA levels were significantly lower in CRC patients compared to healthy controls. Lower CDCA levels were associated with advanced TNM stage, differentiation status, and lymph node metastasis. FXR mRNA was significantly downregulated in CRC tumors and was negatively correlated with tumor aggressiveness. Serum CDCA levels were positively correlated with tumor FXR mRNA expression, and higher FXR expression was associated with better 5-year overall survival. CDCA treatment significantly suppressed CRC cell proliferation and migration in a dose- and time-dependent manner, whereas FXR knockdown attenuated these inhibitory effects. These findings indicated that CDCA suppressed CRC progression by activating FXR and inhibiting Wnt/β-catenin signaling. This highlights the potential of CDCA and FXR as therapeutic targets for CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital) Wuxi 214023, Jiangsu, China.
- Department of General Surgery, Wuxi People's Hospital Affiliated to Nanjing Medical University Wuxi 214023, Jiangsu, China.
- Department of Gastroenterology, Affiliated Hospital of Jiangnan University Wuxi 214122, Jiangsu, China.
Zitieren
APA
Xie, J., He, Y., Xu, C., Wang, S., Qu, G., Ren, Y., Wang, T., & Xue, Y. (2026). Chenodeoxycholic acid suppresses colorectal cancer by activating Farnesoid X receptor. American Journal of Cancer Research, 16(7), 2801-2813. https://doi.org/10.62347/bzhd6251
Vancouver
Xie J, He Y, Xu C, Wang S, Qu G, Ren Y, et al. Chenodeoxycholic acid suppresses colorectal cancer by activating Farnesoid X receptor. American Journal of Cancer Research. 2026;16(7):2801-2813. doi:10.62347/bzhd6251
BibTeX
@article{Xie2026,
author = {Xie, Jun and He, Yiding and Xu, Chenhao and Wang, Sihao and Qu, Guangchuan and Ren, Yilin and Wang, Tong and Xue, Yuzheng},
title = {Chenodeoxycholic acid suppresses colorectal cancer by activating Farnesoid X receptor},
journal = {American Journal of Cancer Research},
year = {2026},
volume = {16},
number = {7},
pages = {2801--2813},
doi = {10.62347/bzhd6251}
}
EUVIMED